SCHEMBL4483474

SCHEMBL4483474

CCOC(=O)c1nc(OC)c(OC)c2c1CCN(Cc1ccc(F)cc1)C2=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
HTT P42858 3/20 0.45
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 2/20 0.42
L3MBTL1 Q9Y468 4/20 0.41
TDP1 Q9NUW8 1/20 0.41
AKR1B1 P15121 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
PKM P14618 1/20 0.38
SCD O00767 1/20 0.37
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
APP P05067 1/20 0.36
MAPT P10636 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4481402 0.92 MEN1 (0.48) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL4502946 0.89 AKR1B1 (0.43) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL1335829 0.83 MEN1 (0.37) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL4477132 0.82 LMNA (0.50) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL10233982 0.82 ALDH1A1 (0.40) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL10232272 0.81 MEN1 (0.40) SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4477812 0.80 LMNA (0.46) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL4484374 0.80 LMNA (0.49) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL10233464 0.78 MEN1 (0.36) SMN1; SMN2MEN1KMT2AALDH1A1AKR1B1
SCHEMBL10232607 0.78 AKR1B1 (0.37) AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP disclosed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H LMNA 4273/4885SMN1; SMN2 4492/4885HTT 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.